← Jiangxi Fushine Pharmaceutical overview

Jiangxi Fushine Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Jiangxi Fushine Pharmaceutical Co Ltd (300497.CS)

Q3 202613 Jul – 28 Sep 2026

▲4

Fushine's profit surge, dividends, and new patent drive gains

First-half profit surge Fushine expects first-half net profit to jump 2,487% to 3,204% year-on-year, one of the strongest earnings rebounds on ChiNext. This huge profit growth makes the stock more attractive to investors and supports a higher share price.
This is the core fundamental driver behind the stock's recent strength.
Interim cash dividend proposed Controlling shareholder Bao Jianhua proposed a 2026 interim cash dividend of 0.5 yuan per 10 shares. Returning cash to shareholders signals confidence and can attract income-focused investors, helping support the stock price.
Dividend announcements are a direct capital return event that can lift investor sentiment.
Japanese patent for protein technology Fushine won a Japanese invention patent for its Fusarium oxysporum mycelial protein technology, adding to patents already held in China, South Korea, and the US. This strengthens its position in the fast-growing alternative protein market and supports long-term growth prospects.
The patent expands the company's technology moat and international business potential.
Q3 profit forecast turns positive Fushine expects first-three-quarter net profit of 350-430 million yuan, up 658-785% year-on-year, swinging from a loss to a profit. This confirms the strong earnings trend is continuing beyond the first half, giving investors more confidence.
The Q3 forecast extends the profit recovery story and reinforces the positive earnings trajectory.

August 202613 Jul – 28 Sep 2026

▲4

Fushine's profit surge, dividends, and new patent drive gains

First-half profit surge Fushine expects first-half net profit to jump 2,487% to 3,204% year-on-year, one of the strongest earnings rebounds on ChiNext. This huge profit growth makes the stock more attractive to investors and supports a higher share price.
This is the core fundamental driver behind the stock's recent strength.
Interim cash dividend proposed Controlling shareholder Bao Jianhua proposed a 2026 interim cash dividend of 0.5 yuan per 10 shares. Returning cash to shareholders signals confidence and can attract income-focused investors, helping support the stock price.
Dividend announcements are a direct capital return event that can lift investor sentiment.
Japanese patent for protein technology Fushine won a Japanese invention patent for its Fusarium oxysporum mycelial protein technology, adding to patents already held in China, South Korea, and the US. This strengthens its position in the fast-growing alternative protein market and supports long-term growth prospects.
The patent expands the company's technology moat and international business potential.
Q3 profit forecast turns positive Fushine expects first-three-quarter net profit of 350-430 million yuan, up 658-785% year-on-year, swinging from a loss to a profit. This confirms the strong earnings trend is continuing beyond the first half, giving investors more confidence.
The Q3 forecast extends the profit recovery story and reinforces the positive earnings trajectory.

Latest13 Jul – 28 Sep 2026

▲4

Fushine's profit surge, dividends, and new patent drive gains

First-half profit surge Fushine expects first-half net profit to jump 2,487% to 3,204% year-on-year, one of the strongest earnings rebounds on ChiNext. This huge profit growth makes the stock more attractive to investors and supports a higher share price.
This is the core fundamental driver behind the stock's recent strength.
Interim cash dividend proposed Controlling shareholder Bao Jianhua proposed a 2026 interim cash dividend of 0.5 yuan per 10 shares. Returning cash to shareholders signals confidence and can attract income-focused investors, helping support the stock price.
Dividend announcements are a direct capital return event that can lift investor sentiment.
Japanese patent for protein technology Fushine won a Japanese invention patent for its Fusarium oxysporum mycelial protein technology, adding to patents already held in China, South Korea, and the US. This strengthens its position in the fast-growing alternative protein market and supports long-term growth prospects.
The patent expands the company's technology moat and international business potential.
Q3 profit forecast turns positive Fushine expects first-three-quarter net profit of 350-430 million yuan, up 658-785% year-on-year, swinging from a loss to a profit. This confirms the strong earnings trend is continuing beyond the first half, giving investors more confidence.
The Q3 forecast extends the profit recovery story and reinforces the positive earnings trajectory.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.